Vaxcyte, Inc.

Vaxcyte, Inc. (PCVX) priced its initial public offering on Jun 15, 2020 at $16.00 per share, within its $14.00–$16.00 range, raising $250M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $774.2M. BofA Securities was lead-left underwriter, joined by Jefferies, Evercore ISI and Cantor and others. Cooley advised the company and Latham & Watkins advised the underwriters.

Vaxcyte, Inc. is a vaccine company developing novel vaccines to prevent or treat common infectious diseases. Its cell-free protein synthesis platform, licensed from Sutro Biopharma, produces vaccine building blocks, and its lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine expected to enter clinical trials in the second half of 2021.

Status

IPO

Ticker

PCVX

Exchange

Nasdaq Global Select

Priced

Jun 15, 2020

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$250M

Market cap at IPO price

$774.2M

First filed

May 22, 2020

Underwriters

BofA Securities, Jefferies, Evercore ISI, Cantor and Needham

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.